Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 7/20 | 0.42 |
| ▸ | HMGCR | P04035 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 3/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3775780 | 0.89 | HTR2A (0.41) | MTNR1AMTNR1BHTR2AKDM1AHTR2C | |
| SCHEMBL29660928 | 0.86 | HTR2A (0.53) | HTR2AHTR2CTAAR1 | |
| SCHEMBL16651484 | 0.86 | HTR2A (0.49) | HTR2AHTR2CTAAR1 | |
| SCHEMBL3993092 | 0.86 | HTR2A (0.53) | HTR2AHTR2CTAAR1 | |
| SCHEMBL25219237 | 0.85 | HTR2A (0.43) | HTR2AHTR2CTAAR1HTR2BCYP3A4 | |
| SCHEMBL6738129 | 0.84 | TAAR1 (0.51) | HTR2AHTR2CTAAR1HTR2B | |
| SCHEMBL3884189 | 0.84 | HTR2A (0.50) | HTR2AHMGCRHTR2CTAAR1HTR2B | |
| SCHEMBL13618030 | 0.80 | TAAR1 (0.53) | MTNR1AMTNR1BHMGCRKDM1ATAAR1 | |
| SCHEMBL18867908 | 0.79 | HTR2A (0.48) | MTNR1AMTNR1BHTR2AHMGCRHTR2C | |
| SCHEMBL17010160 | 0.79 | HTR2A (0.48) | MTNR1AMTNR1BHTR2AHMGCRHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2145888-A1 | Deazapurine derivatives as HSP90-Inhibitors | Conforma Therapeutics Corporation (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20070185064-A1 | 2-Aminopurine Analogs Having HSP90-Inhibiting Activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-08-09 | — | — | US | disclosed |
| US-7138401-B2 | 2-aminopurine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1670802-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | Conforma Therapeutic Corporation (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050113340-A1 | 2-Aminopurine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION | 2005-05-26 | — | — | US | disclosed |
| WO-2005028434-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
| EP-0027993-A1 | 6-Fluorodihydroxyphenylalanines, a process for preparing and a pharmaceutical composition containing the same | MERCK & CO. INC. (US) | 1981-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113340-A1 | 2-Aminopurine analogs having HSP90-inhibiting activity | HSP90AB2P, HSP90AB1, HSP90AA1 | MTNR1A 3707/4885MTNR1B 3303/4885HTR2A 1322/4885 |
| US-20070185064-A1 | 2-Aminopurine Analogs Having HSP90-Inhibiting Activity | HSP90AB2P, HSP90AB1, HSP90AA1 | MTNR1A 3707/4885MTNR1B 3303/4885HTR2A 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.